Literature DB >> 26948378

The First Report of a 290-bp Deletion in β-Globin Gene in the South of Iran.

Mohammad Hamid1,2, Ladan Dawoody Nejad1, Gholamreza Shariati2,3, Hamid Galehdari3, Alihossein Saberi2,3, Marziye Mohammadi-Anaei2.   

Abstract

BACKGROUND: β-thalassemia is one of the most widespread disease in the world, including Iran. In this study, we reported, for the first time, a 290-bp β-globin gene deletion in the south of Iran.
METHODS: Four individuals from three unrelated families with Arabic ethnic background were studied in Khuzestan Province. Red blood cell indices and hemoglobin analysis were carried out according to the standard methods. Genomic DNA was obtained from peripheral blood cells by salting out procedures. β-globin gene amplification, multiplex ligation-dependent probe amplification (MLPA) and DNA sequencing were performed.
RESULTS: The PCR followed by sequencing and MLPA test of the β-globin gene confirmed the presence of a 290-bp deletion in the heterozygous form, along with -88C>A mutation. All the individuals had elevated hemoglobin A2 and normal fetal hemoglobin levels.
CONCLUSIONS: This mutation causes β0-thalassemia and can be highly useful for prenatal diagnosis in compound heterozygous condition with different β-globin gene mutations.

Entities:  

Keywords:  β-thalassemia; β-globin gene mutation; Iran; Multiplex ligation-dependent probe amplification

Year:  2016        PMID: 26948378      PMCID: PMC5274712          DOI: 10.18869/acadpub.ibj.21.2.126

Source DB:  PubMed          Journal:  Iran Biomed J        ISSN: 1028-852X


INTRODUCTION

β -thalassemia is one of the most frequent genetic disorders in Iran with a great mutational diversity. More than 280 mutations have been identified in association with β-thalassemia in the country. Mutations are mostly single base substitutions, and in some cases, they may cause deletions or insertions of different regions in a gene[1,2]. β-globin gene deletions, especially those in promoter regions, are usually associated with the high levels of hemoglobin A2 (HbA2) in heterozygous individuals. In addition, the high levels of fetal hemoglobin (HbF) are detected because of δβ-globin gene deletions. However, large deletions of δβ- and γ-globin genes are observed among some carriers with normal levels of HbF. Since most deletions may be missed by DNA sequencing, the identification of deletions in β-globin gene by other means is of great important[3,4]. In the current study, we detected a 290-bp deletion in four individuals from three unrelated families with Arabic ethnic background in Khuzestan Province, south of Iran.

MATERIALS AND METHODS

The present investigation is a part of a national program for the prevention of thalassemia. In total, four individuals who referred to the Narges Prenatal Diagnostics and Medical Genetics Laboratory (Ahvaz, Iran) during three years participated in this study. The analysis of red blood cell indices and Hb analysis were carried out according to the standard methods. Following a written informed consent from the subjects, some molecular studies were conducted on the genomic DNA isolated from peripheral blood cells using a salting out procedure[5]. To identify α-thalassemia genotype, the common Mediterranean α-globin gene deletions were investigated by Gap-PCR as described elsewhere[6]. β-globin gene was amplified and directly sequenced by the chain termination method[7] on the ABI PRISM 3130 Genetic Analyzer (Applied Biosystems, Foster City, CA, USA). For detection of deletions, multiplex ligation-dependent probe amplification (MLPA) assay was performed using the SALSA MLPA kit P102 HBB (MRC-Holland, Amsterdam, Netherlands). Then amplified fragments were separated by capillary electrophoresis on the ABI PRISM 3130 Genetic Analyzer (Applied Biosystems, Foster city, CA, USA) and analyzed by GeneMarker software v.1.6 (Soft Genetics, State College, PA, USA).

RESULTS

This study reported, for the first time, a 290-bp deletion (c.-176_92+25del) in β-globin gene in four individuals from three unrelated families with Arabic ethnic background in Khuzestan Province. All the individuals had elevated HbA2 and normal HbF levels. One of the individuals, offspring of K.B., was a 5-year-old girl, who inherited both defects (290-bp deletion/-88C>A mutation) from her parents. Physical examination of the patient indicated pallor, slight hepatosplenomegaly. The hematological and molecular data of the studied subjects are summarized in Table 1.
Table 1

The hematological and molecular data of the studied subjects

S.M.M.M.K.B.Offspring of K.B.
Age (year)1824485
GenderFMMF
Hb (g/dl)10.911.512.56.4
RBC (1012/L)5.196.335.993.58
MCV(fl)64.564.866.859.3
MCH (pg)2121.820.917.9
MCHC (%)32.5-31.330.2
HbA (%)94.692.9-94.8
HbF (%)0.40.6-0.0
HbA2 (%)56.5-5.2
β-genotype290-bp deletion/N290-bp deletion/N290-bp deletion /N290-bp deletion/-88 C>A
α-genotypeαα/αααα/αααα/αααα/αα
OriginArabArabArabArab

F, female; M, male; N, normal

The hematological and molecular data of the studied subjects F, female; M, male; N, normal The 290-bp deletion was characterized by DNA sequencing and MLPA test. The mutation removed the region between positions -125 and +78 relative to the β-globin gene mRNA cap site. The MLPA results confirmed the deletion by probes ranging from prob 21 (Promoter) to prob 1 (HBB intron 1) (Fig. 1). Generally, no mutation or deletion was found in the α-globin genes of the studied individuals.
Fig. 1

The chromatogram and histogram of multiplex ligation-dependent probe amplification (MLPA) dosage showing a 290-bp deletion on β-globin gene. (a) The sequence of a 290-bp deletion presenting in heterozygosity; (b) The histogram of MLPA showing a 290-bp deletion.

The chromatogram and histogram of multiplex ligation-dependent probe amplification (MLPA) dosage showing a 290-bp deletion on β-globin gene. (a) The sequence of a 290-bp deletion presenting in heterozygosity; (b) The histogram of MLPA showing a 290-bp deletion.

DISCUSSION

The 290-bp deletion was first observed in a Turkish patient and later in many other patients[8-11]. In the present investigation, we reported, for the first time, a 290-bp deletion along with -88C>A mutation in the south of Iran. The mutation removed the region between positions -125 and +78 relative to the β-globin gene mRNA cap site. According to a previous study[12], -88C>A mutation allows the β-locus control region to interact with the promoters of δ- and γ-globin genes by competition between fetal and adult globin genes, which result in HbA2 and HbF levels[12]. However, our samples with a 290-bp deletion were just associated with the increased levels of HbA2 and normal HbF. Some of the deleted elements in positions -125 and +78 are the CAC (−90), CAAT (−70) and TATA (−30) boxes. The absence of these elements is led to increased HbA2 levels without any effect on γ-globin genes, which is in contrast to the previous reports[8-10,13]. The detection of this β-thalassemia deletion in the promoter region, which is an available place for transcription factors, can be highly useful for prenatal diagnosis as the consanguineous and ethnic marriages in families compatible the control of the disease.
  11 in total

1.  Single-tube multiplex-PCR screen for common deletional determinants of alpha-thalassemia.

Authors:  S S Chong; C D Boehm; D R Higgs; G R Cutting
Journal:  Blood       Date:  2000-01-01       Impact factor: 22.113

2.  A 13-bp deletion in the 3' untranslated region of the β-globin gene causes β-thalassemia major in compound heterozygosity with IVSII-1 mutation.

Authors:  Mohammad Hamid; Mohammad Taghi Akbari
Journal:  Med Princ Pract       Date:  2011-07-11       Impact factor: 1.927

3.  A simple salting out procedure for extracting DNA from human nucleated cells.

Authors:  S A Miller; D D Dykes; H F Polesky
Journal:  Nucleic Acids Res       Date:  1988-02-11       Impact factor: 16.971

4.  An approximately 300 bp deletion involving part of the 5' beta-globin gene region is observed in members of a Turkish family with beta-thalassemia.

Authors:  J C Diaz-Chico; K G Yang; A Kutlar; A L Reese; M Aksoy; T H Huisman
Journal:  Blood       Date:  1987-08       Impact factor: 22.113

5.  A beta-thalassemia gene caused by a 290-base pair deletion: analysis by direct sequencing of enzymatically amplified DNA.

Authors:  R Spiegelberg; C Aulehla-Scholz; H Erlich; J Horst
Journal:  Blood       Date:  1989-05-01       Impact factor: 22.113

6.  A beta-thalassemia mutant caused by a 300-bp deletion in the human beta-globin gene.

Authors:  C Aulehla-Scholz; R Spiegelberg; J Horst
Journal:  Hum Genet       Date:  1989-02       Impact factor: 4.132

Review 7.  Genetic modifiers of beta-thalassemia.

Authors:  Swee Lay Thein
Journal:  Haematologica       Date:  2005-05       Impact factor: 9.941

8.  HbS/beta(del)-thalassemia associated with high levels of hemoglobins A2 and F in a Turkish family.

Authors:  G O Tadmouri; L Yüksel; A N Başak
Journal:  Am J Hematol       Date:  1998-09       Impact factor: 10.047

9.  The Iranian Human Mutation Gene Bank: a data and sample resource for worldwide collaborative genetics research.

Authors:  Hossein Najmabadi; Maryam Neishabury; Farhad Sahebjam; Kimia Kahrizi; Yousef Shafaghati; Nushin Nikzat; Maryam Jalalvand; Farahnaz Aminy; Susan Bany Hashemi; Babak Moghimi; Ali Reza Noorian; Ali Jannati; Mehrdad Mohammadi; Khalil Javan
Journal:  Hum Mutat       Date:  2003-02       Impact factor: 4.878

Review 10.  Genetic modifiers of the beta-haemoglobinopathies.

Authors:  Swee Lay Thein
Journal:  Br J Haematol       Date:  2008-05       Impact factor: 6.998

View more
  2 in total

1.  Identifying genetic variants and pathways associated with extreme levels of fetal hemoglobin in sickle cell disease in Tanzania.

Authors:  Siana Nkya; Liberata Mwita; Josephine Mgaya; Happiness Kumburu; Marco van Zwetselaar; Stephan Menzel; Gaston Kuzamunu Mazandu; Raphael Sangeda; Emile Chimusa; Julie Makani
Journal:  BMC Med Genet       Date:  2020-06-05       Impact factor: 2.103

2.  Comparison of decayed, missing, filled teeth index between thalassemia major patients and control group in Iran: a systematic review and meta-analysis.

Authors:  Mahmood Moosazadeh; Nadia Elyassi Gorji; Pegah Nasiri; Ali Malekzadeh Shafaroudi
Journal:  BDJ Open       Date:  2020-11-17
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.